Literature DB >> 18189292

Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.

Daniel S Kapp1, Jacob Y Shin, John K Chan.   

Abstract

BACKGROUND: The objectives of the current study were to determine the prognostic factors associated with disease-specific survival (DSS) and to analyze the role of lymphadenectomy (LND) and oophorectomy in the management of uterine leiomyosarcomas (LMS).
METHODS: Data were abstracted from the Surveillance, Epidemiology, and End Results database (1988-2003). Kaplan-Meier and Cox proportional hazards regression models were used for analyses.
RESULTS: The median age of the 1396 patients was 52 years. There were 951 patients (68.1%) with International Federation of Gynecology and Obstetrics (FIGO) stage I disease, 43 patients (3.1%) with stage II disease, 99 patients (7.1%) with stage III disease, and 303 patients (21.7%) with stage IV disease. Distribution by tumor grade included 87 patients with grade 1 tumors, 208 with grade 2, and 509 patients with grade 3 tumors. The 5-year DSS rates for patients with stage I, II, III, and IV disease were 75.8%, 60.1%, 44.9%, and 28.7%, respectively. Lymph node metastases were identified in 23 of 348 patients (6.6%) who underwent LND. The 5-year DSS rate was 26% in patients who had positive lymph nodes compared with 64.2% in patients who had negative lymph nodes (P < .001). Of 341 patients aged <50 years with stage I or II disease, 240 (70.4%) underwent oophorectomy. There was no difference in 5-year DSS based on oophorectomy. On multivariate analysis, older age at diagnosis, more recent year of diagnosis, African-American race, higher tumor grade, higher stage of disease, and lack of primary surgical treatment all were associated significantly with worse survival.
CONCLUSIONS: Independent predictors of DSS in patients with uterine LMS included age, race, stage, grade, and primary surgery. Oophorectomy was not found to have an independent impact on survival. Cancer 2008. (c) 2008 American Cancer Society.

Entities:  

Mesh:

Year:  2008        PMID: 18189292     DOI: 10.1002/cncr.23245

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  78 in total

1.  A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.

Authors:  Oliver Zivanovic; Lindsay M Jacks; Alexia Iasonos; Mario M Leitao; Robert A Soslow; Emanuela Veras; Dennis S Chi; Nadeem R Abu-Rustum; Richard R Barakat; Murray F Brennan; Martee L Hensley
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

2.  Novel High-grade Endometrial Stromal Sarcoma: A Morphologic Mimicker of Myxoid Leiomyosarcoma.

Authors:  Lien N Hoang; Amandeep Aneja; Niamh Conlon; Deborah F Delair; Sumit Middha; Ryma Benayed; Martee L Hensley; Kay J Park; Travis J Hollmann; Meera R Hameed; Cristina R Antonescu; Robert A Soslow; Sarah Chiang
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

3.  Uterine leiomyosarcomas with osteoclast-like giant cells associated with high expression of RUNX2 and RANKL.

Authors:  Mika Terasaki; Yasuhiro Terasaki; Kyoko Wakamatsu; Naomi Kuwahara; Koichi Yoneyama; Rieko Kawase; Keisuke Kurose; Etsuko Toda; Yoko Endo; Shinobu Kunugi; Yusuke Kajimoto; Akira Shimizu
Journal:  Virchows Arch       Date:  2021-01-06       Impact factor: 4.064

4.  Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

Authors:  Rebecca C Arend; Michael D Toboni; Allison M Montgomery; Robert A Burger; Alexander B Olawaiye; Bradley J Monk; Thomas J Herzog
Journal:  Oncologist       Date:  2018-08-23

Review 5.  A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature.

Authors:  Fong W Liu; Valerie B Galvan-Turner; Krista S Pfaendler; Teresa C Longoria; Robert E Bristow
Journal:  Am J Obstet Gynecol       Date:  2015-01-09       Impact factor: 8.661

6.  BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology.

Authors:  Sarah Chiang; Cheng-Han Lee; Colin J R Stewart; Esther Oliva; Lien N Hoang; Rola H Ali; Martee L Hensley; Javier A Arias-Stella; Denise Frosina; Achim A Jungbluth; Ryma Benayed; Marc Ladanyi; Meera Hameed; Lu Wang; Yu-Chien Kao; Cristina R Antonescu; Robert A Soslow
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

Review 7.  Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.

Authors:  Martee L Hensley; Brigitte A Barrette; Klaus Baumann; David Gaffney; Anne L Hamilton; Jae-Weon Kim; Johanna U Maenpaa; Patricia Pautier; Nadeem Ahmad Siddiqui; Anneke M Westermann; Isabelle Ray-Coquard
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

8.  [Uterine sarcoma treatment].

Authors:  G Köhler
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

Review 9.  Uterine sarcoma 2008.

Authors:  Jeff F Lin; Brian M Slomovitz
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

10.  Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.

Authors:  Kristelle Lusby; Kari Brewer Savannah; Elizabeth G Demicco; Yiqun Zhang; Markus Ph Ghadimi; Eric D Young; Chiara Colombo; Ryan Lam; Tugce E Dogan; Jason L Hornick; Alexander J Lazar; Kelly K Hunt; Matthew L Anderson; Chad J Creighton; Dina Lev; Raphael E Pollock
Journal:  Ann Surg Oncol       Date:  2013-01-20       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.